A combination of intismeran autogene and Keytruda significantly prolonged recurrence-free survival in melanoma.
Moderna’s (MRNA) mRNA-based cancer therapy, intismeran autogene (mRNA-4157), with Merck’s (MRK) anti-PD-1 therapy, Keytruda, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results